Editas Medicine
Market Cap
US$1.2b
Last Updated
2019/09/22 00:28 UTC
Data Sources
Company Financials +
Executive Summary
Editas Medicine, Inc. operates as a clinical stage genome editing company.
Snowflake
Fundamentals
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Editas Medicine's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.0%
EDIT
1.0%
US Biotechs
-0.6%
US Market
1 Year Return
-17.0%
EDIT
-10.8%
US Biotechs
0.7%
US Market
EDIT underperformed the Biotechs industry which returned -10.8% over the past year.
EDIT underperformed the Market in United States of America which returned 0.6% over the past year.
Share holder returns
| EDIT | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.0% | 1.0% | -0.6% |
| 30 Day | 3.9% | 0.3% | 2.9% |
| 90 Day | 14.7% | -1.1% | 1.3% |
| 1 Year | -17.0%-17.0% | -10.1%-10.8% | 2.9%0.7% |
| 3 Year | 72.8%72.8% | 5.8%2.2% | 44.6%35.2% |
| 5 Year | n/a | 3.7%-1.3% | 61.9%44.2% |
Price Volatility Vs. Market
How volatile is Editas Medicine's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
The CEO, President & Director of Editas Medicine, Inc. (NASDAQ:EDIT), Cynthia Collins, Just Sold 31.3% Of Their Holding1 month ago | Simply Wall St
Need To Know: Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Have Been Buying Shares2 months ago | Simply Wall St
What Kind Of Shareholders Own Editas Medicine, Inc. (NASDAQ:EDIT)?Valuation
Is Editas Medicine undervalued based on future cash flows and its price relative to the stock market?
6.32x
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Editas Medicine to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Editas Medicine to establish if it is available at substantial discount.
Price Based on Earnings
Editas Medicine is loss making, we can't compare its value to the US Biotechs industry average.
Editas Medicine is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Editas Medicine, we can't assess if its growth is good value.
Price Based on Value of Assets
Editas Medicine is overvalued based on assets compared to the US Biotechs industry average.
Next Steps
Future Growth
How is Editas Medicine expected to perform in the next 1 to 3 years based on estimates from 6 analysts?
-8.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Editas Medicine's revenue is expected to grow significantly at over 20% yearly.
Editas Medicine is not considered high growth as it is expected to be loss making for the next 1-3 years.
Editas Medicine's revenue growth is expected to exceed the United States of America market average.
Unable to compare Editas Medicine's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
Unable to compare Editas Medicine's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Earnings per Share Growth Estimates
Future Return on Equity
Unable to establish if Editas Medicine will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Next Steps
Past Performance
How has Editas Medicine performed over the past 5 years?
-23.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Editas Medicine does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Editas Medicine's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Editas Medicine's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Editas Medicine has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Editas Medicine has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Editas Medicine improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Next Steps
Financial Health
How is Editas Medicine's financial position?
Financial Position Analysis
Editas Medicine is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Editas Medicine's cash and other short term assets cover its long term commitments.
Debt to Equity History and Analysis
Editas Medicine's level of debt (0%) compared to net worth is satisfactory (less than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (7% vs 0% today).
Balance Sheet
Low level of unsold assets.
Debt is not covered by short term assets, assets are -9.1265446448663E+16x debt.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Editas Medicine has sufficient cash runway for more than 3 years based on current free cash flow.
Editas Medicine has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 35.5% each year.
Next Steps
Dividend
What is Editas Medicine's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Editas Medicine's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Editas Medicine's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Editas Medicine has not reported any payouts.
Unable to verify if Editas Medicine's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Editas Medicine has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
Next Steps
Management
What is the CEO of Editas Medicine's salary, the management and board of directors tenure and is there insider trading?
5.5yrs
Average management tenure
CEO
Cindy Collins (61yo)
0.5yrs
Tenure
US$479,814
Compensation
Ms. Cynthia L. Collins, also Known as Cindy, has been a Director of Editas Medicine, Inc. since December 10, 2018 and its Chief Executive Officer since August 6, 2019 and President since June 12, 2019. She ...
Management Age and Tenure
5.5yrs
Average Tenure
61yo
Average Age
The average tenure for the Editas Medicine management team is over 5 years, this suggests they are a seasoned and experienced team.
Board Age and Tenure
1.9yrs
Average Tenure
60yo
Average Age
The average tenure for the Editas Medicine board of directors is less than 3 years, this suggests a new board.
Insider Trading
Editas Medicine individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 5,193 |
| Max Price | US$25.83 |
| Entity | Individual |
| Shares | 10,200 |
| Max Price | US$23.94 |
Ownership Breakdown
Management Team
George Church (65yo)
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
David Liu
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
Cindy Collins (61yo)
CEO, President & Director
- Tenure: 0.5yrs
- Compensation: US$479.81k
Mark Mullikin
Senior Director of Finance & Investor Relations
- Tenure: 0yrs
Feng Zhang
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
J. Joung
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
Vic Myer (52yo)
Chief Technology Officer
- Tenure: 4.4yrs
- Compensation: US$2.46m
Charlene Stern
Vice President of Legal
- Tenure: 0yrs
Charlie Albright (61yo)
Chief Scientific Officer
- Tenure: 3.1yrs
- Compensation: US$2.39m
Eric Ek
Interim CFO
- Tenure: 0.5yrs
Board Members
Jim Mullen (60yo)
Chairman of the Board
- Tenure: 1.5yrs
- Compensation: US$612.36k
George Church (65yo)
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
Terry Flotte
Scientific Advisory Board Member
- Tenure: 0yrs
Akshay Vaishnaw (56yo)
Director
- Tenure: 3.2yrs
- Compensation: US$349.50k
David Liu
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
Cindy Collins (61yo)
CEO, President & Director
- Tenure: 0.5yrs
- Compensation: US$479.81k
Andrew Hirsch (48yo)
Director
- Tenure: 2.3yrs
- Compensation: US$357.03k
Feng Zhang
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
J. Joung
Co-Founder & Scientific Advisory Board Member
- Tenure: 0yrs
Charles Gersbach
Scientific Advisory Board Member
- Tenure: 0yrs
Company Information
Editas Medicine, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Editas Medicine, Inc.
- Ticker: EDIT
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.223b
- Shares outstanding: 48.92m
- Website: https://www.editasmedicine.com
Number of Employees
Location
- Editas Medicine, Inc.
- 11 Hurley Street
- Cambridge
- Massachusetts
- 2141
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EDIT | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 2016 |
| 8EM | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2016 |
| 0IFK | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Feb 2016 |
Biography
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/09/22 00:28 |
| End of Day Share Price | 2019/09/20 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.